<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366093</url>
  </required_header>
  <id_info>
    <org_study_id>190-054</org_study_id>
    <nct_id>NCT00366093</nct_id>
  </id_info>
  <brief_title>Study of Eszopiclone Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause/Menopause</brief_title>
  <official_title>The Efficacy of Eszopiclone 3 mg Compared to Placebo in the Treatment of Insomnia Secondary to Perimenopause or Menopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate improved subjective sleep in women with insomnia secondary to perimenopause or
      menopause following treatment with 3 mg of eszopiclone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of
      eszopiclone 3 mg in women with insomnia secondary to perimenopause or menopause. Eligible
      subjects will be randomized to either eszopiclone 3 mg or placebo nightly for four weeks.
      This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired
      by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to
      Sunovion Pharmaceuticals Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean subjective SL</measure>
    <time_frame>Week 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean subjective WASO</measure>
    <time_frame>Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean subjective SL</measure>
    <time_frame>Weeks 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean subjective WASO</measure>
    <time_frame>Weeks 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean subjective TST</measure>
    <time_frame>Weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of awakenings</measure>
    <time_frame>Weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality and depth</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime alertness</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to concentrate</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical well-being</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to function</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean subjective number of nocturnal awakenings due to hot flashes</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of hot flashes per day</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of nocturnal hot flashes per night</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean severity of hot flashes</measure>
    <time_frame>Weeks 1, 2, 3, and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESS score</measure>
    <time_frame>Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ISI score</measure>
    <time_frame>Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GCS score</measure>
    <time_frame>Weeks 2 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SDS score</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MenQOL score</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MADRS score</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>withdrawal effects will be assessed for the ISI, ESS, MADRS, MenQOL, Greene Climacteric Scale, Sheehan Disability Scale, and Physician Global Assessment.</measure>
    <time_frame>Week 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">410</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>eszopiclone 3 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eszopiclone</intervention_name>
    <description>eszopiclone 3 mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lunesta</other_name>
    <other_name>S-zopiclone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablet</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subject must understand the purpose of the study and be willing to adhere to the study
             schedule and procedures described in this protocol.

          -  Subject must be between the ages of 40 and 60 years, inclusive, on the day of signing
             consent.

          -  Subject must have perimenopausal or menopausal signs and symptoms.

          -  Subject must report SL of &gt;45 minutes and &lt;6 hours of TST at least three times a week
             over the previous month and symptoms of insomnia must post date onset of
             perimenopausal or menopausal symptoms.

          -  Subject's physical exam must show no clinically significant abnormal findings (other
             than insomnia and menopause symptoms) at screening.

        Exclusion Criteria

          -  Subject has history of circadian rhythm disorder, or travels across &gt;3 time zones on a
             regular basis.

          -  Female subject is pregnant, lactating or within 6-months post partum.

          -  Subject has a history of drug or alcohol abuse or dependence in the past 2 years or
             positive urine drug test at screening .

          -  Subject has unstable medical abnormality, or unstable chronic disease; or history of
             significant cardiac, renal, or hepatic disease, seizure disorder, or current or past
             acute suicidal tendencies.

          -  Subject has participated in any investigational drug study within 30 days prior to
             screening or plans to participate in another investigational drug study during
             participation in this study.

          -  Subject is taking hormone replacement therapy or an hormonal contraceptive, and has
             not been on a stable dose for a minimum of 60 days prior to study start.

          -  Subject is known to be seropositive for HIV.

          -  Subject has a disorder or history of a condition (e.g., malabsorption,
             gastrointestinal surgery) that may interfere with drug absorption distribution,
             metabolism, or excretion.

          -  Subject has a history of malignancy within 5 years, or current malignancy, except for
             non-melanoma skin cancer.

          -  Subject has a diagnosis of any psychiatric disorder as identified by a psychiatric
             screening questionnaire.

          -  Subject has any primary diagnosis (personality disorder or mental retardation) that
             would impact the investigator's ability to evaluate the safety or efficacy of the
             study medication.

          -  Subject has difficulties in sleep initiation or maintenance associated with other
             known primary sleep disorders [e.g. sleep apnea, restless leg syndrome (RLS), or
             periodic leg movement syndrome (PLMS)], or has any condition that may affect sleep
             (e.g., chronic pain, urinary incontinence, etc.).

          -  Subject has used any drugs known or suspected to affect hepatic or renal clearance
             capacity within a period of 30 days prior to screening.

          -  Subject reports consumption of more than two alcoholic beverages daily, 14 or more
             alcoholic beverages weekly, or five or more alcoholic beverages on any given day.

          -  Subject is a rotating or third/night shift worker.

          -  Subject is a staff member or relative of a staff member.

          -  Subject is experiencing symptoms of premature menopause or surgical menopause.

          -  Subject has discontinued hormone replacement therapy or a hormonal contraceptive, and
             has not been off treatment for a minimum of 60 days prior to study start.

          -  Subject has been on hormone replacement therapy or hormonal contraceptives for greater
             then one year.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newington</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Meyers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seatle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2006</study_first_submitted>
  <study_first_submitted_qc>August 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2006</study_first_posted>
  <last_update_submitted>February 21, 2012</last_update_submitted>
  <last_update_submitted_qc>February 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menopause</keyword>
  <keyword>Perimenopause</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

